Human MEK2 (MAP2K2) activation kit by CRISPRa

CAT#: GA103795

MAP2K2 CRISPRa kit - CRISPR gene activation of human mitogen-activated protein kinase kinase 2

Product Images

Specifications

Product Data

• Format: 3 gRNAs (5ug each), 1 scramble ctrl (10ug) and 1 enhancer vector (10ug)
• Symbol: MAP2K2
• Locus ID: 5605
• Kit Components:

  GA103795G1, MEK2 gRNA vector 1 in pCas-Guide-GFP-CRISPRa

  GA103795G2, MEK2 gRNA vector 2 in pCas-Guide-GFP-CRISPRa

  GA103795G3, MEK2 gRNA vector 3 in pCas-Guide-GFP-CRISPRa

  1 CRISPRa-Enhancer vector, SKU GE100056

  1 CRISPRa scramble vector, SKU GE100077

• Disclaimer: These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPRa SAM technology. The efficiency of the activation can be affected by many factors, including nucleosome occupancy status, chromatin structure and the gene expression level of the target, etc.

Reference Data

• RefSeq: NM_030662
• UniProt ID: P36507
• Synonyms: CFC4; MAPKK2; MEK2; MKK2; PRKMK2
• Summary: The protein encoded by this gene is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase is known to play a critical role in mitogen growth factor signal transduction. It phosphorylates and thus activates MAPK1/ERK2 and MAPK2/ERK3. The activation of this kinase itself is dependent on the Ser/Thr phosphorylation by MAP kinase kinase kinases. Mutations in this gene cause cardiofaciocutaneous syndrome (CFC syndrome), a disease characterized by heart defects, cognitive disability, and distinctive facial features similar to those found in Noonan syndrome. The inhibition or degradation of this kinase is also found to be involved in the pathogenesis of Yersinia and anthrax. A pseudogene, which is located on chromosome 7, has been identified for this gene. [provided by RefSeq, Jul 2008]